NCT06449209 2026-04-17
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
BioNTech SE
Phase 2 Active not recruiting
Clinical Trials
65 trialsNCT07155174 2026-04-14
SEZanne
AbbVie
Phase 2 Recruiting
NCT05903092 2026-04-07
MOZART
Hoosier Cancer Research Network
Phase 2 Suspended
NCT05957510 2026-04-03
Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment
Guangdong Association of Clinical Trials
Phase 2 Recruiting
NCT07296809 2026-04-02
SKB500 Combinations in Patients With Small Cell Lung Cancer
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 2 Recruiting
NCT07001995 2026-03-16
Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression
Hunan Province Tumor Hospital
Phase 2 Not yet recruiting
NCT05068232 2026-03-04
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
University of Chicago
Phase 2 Recruiting
NCT06830694 2026-02-23
Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment
Samsung Medical Center
Phase 2 Recruiting
NCT04745689 2025-12-10
TAZMAN
AstraZeneca
Phase 2 Active not recruiting
NCT07245446 2025-11-24
A Study of Ivonescimab in First-Line ES-SCLC
Akeso
Phase 2 Recruiting
NCT04702880 2025-10-08
A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer
Bristol-Myers Squibb
Phase 2 Active not recruiting
NCT04472949 2025-10-01
Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).
Swiss Cancer Institute
Phase 2 Active not recruiting
NCT03041311 2025-09-25
Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC
G1 Therapeutics, Inc.
Phase 2 Completed
NCT06838208 2025-09-24
Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC
Anhui Provincial Cancer Hospital
Phase 2 Recruiting
NCT05796089 2025-08-26
CHEST RT
Trans Tasman Radiation Oncology Group
Phase 2 Active not recruiting
NCT04924101 2025-07-23
KEYNOTE-B99
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT07061535 2025-07-11
STAR-SCLC
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Not yet recruiting
NCT03382561 2025-07-03
Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT05800587 2025-04-04
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
Fox Chase Cancer Center
Phase 2 Recruiting
NCT06663098 2025-03-13
CARRY-ON
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2 Recruiting
NCT06786312 2025-01-22
A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT05309629 2025-01-17
Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy in Extensive-Stage Small Cell Lung Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 2 Completed
NCT06769971 2025-01-10
Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC
Sichuan University
Phase 2 Recruiting
NCT04923776 2024-12-30
Liver Directed RT + Chemo-immunotherapy for ES-SCLC
Columbia University
Phase 2 Terminated
NCT04951115 2024-11-26
A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer
Weill Medical College of Cornell University
Phase 2 Terminated
NCT06698965 2024-11-21
Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin
Shanghai Chest Hospital
Phase 2 Recruiting
NCT00686985 2024-09-20
DOCAR
Jeroen Bosch Ziekenhuis
Phase 2 Completed
NCT06536868 2024-08-05
Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC
Second Hospital of Shanxi Medical University
Phase 2 Recruiting
NCT04622228 2024-07-29
Match
Hoffmann-La Roche
Phase 2 Completed
NCT06295926 2024-07-22
Serplulimab Combined With CCRT for LS-SCLC.
Peking Union Medical College Hospital
Phase 2 Recruiting
NCT06497530 2024-07-12
Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC
Guangzhou Institute of Respiratory Disease
Phase 2 Not yet recruiting
NCT04730999 2024-07-05
CeLEBrATE
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2 Completed
NCT04562337 2024-07-03
SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in ES-SCLC
Shandong Cancer Hospital and Institute
Phase 2 Active not recruiting
NCT05765825 2024-06-20
Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC
Sichuan University
Phase 2 Recruiting
NCT06375109 2024-04-19
NeoSCLC-001
Beijing Chest Hospital, Capital Medical University
Phase 2 Not yet recruiting
NCT04610684 2024-03-13
Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases
Hoosier Cancer Research Network
Phase 2 Terminated
NCT06306560 2024-03-12
A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC.
Harbin Medical University
Phase 2 Not yet recruiting
NCT05092412 2024-01-12
Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC
Sichuan University
Phase 2 Unknown
NCT03913455 2023-12-20
Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer
Hoosier Cancer Research Network
Phase 2 Completed
NCT06177925 2023-12-20
A Phase â…¡ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC
Nanfang Hospital, Southern Medical University
Phase 2 Recruiting
NCT02580994 2023-12-11
REACTION
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT04539977 2023-05-09
PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Recruiting
NCT04542369 2023-05-03
Pilot Study of PD-1inhibitor (Tislelizumab) Plus Chemotherapy as Neoadjuvant Therapy for Limited-Stage Small-Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Unknown
NCT05484583 2022-08-05
Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Phase 2 Not yet recruiting
NCT05354700 2022-05-04
A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer
Shanghai Henlius Biotech
Phase 2 Unknown
NCT00695292 2021-11-22
Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT02934503 2021-11-16
Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC)
NYU Langone Health
Phase 2 Terminated
NCT02722369 2021-03-18
STUDY 15 - Comparing Gemcitabine/Carboplatin and Hydroxychloroquine Versus Carboplatin/Etoposide Therapy Alone in Small Cell Lung Cancer (SCLC)
University College, London
Phase 2 Terminated
NCT03059667 2021-02-10
Immunotherapy as Second-line in Patient With Small Cell Lung Cancer
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Completed
NCT04740021 2021-02-05
Study of LP002 in Combination With Chemotherapy for Patients With Extensive Stage Small Cell Lung Cancer
Taizhou HoudeAoke Biomedical Co., Ltd.
Phase 2 Unknown